<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial</h2>
    <div class="badge">2025-09-08T17:25:58+00:00</div>
    <ul>
      <li>Pharmaceuticals industry, which had an 11.5% decline.</li>
<li>market, which gained 20.8% over the past year, and the U.S.</li>
<li>This announcement likely played a key role in the company’s 16% share price rise over the past month.</li>
<li>Over the past five years, Eli Lilly&#x27;s total shareholder return, inclusive of share price appreciation and dividends, reached 416.18%, demonstrating significant longer-term performance.</li>
<li>Currently, the company&#x27;s shares trade at US$727.21, showing a considerable discount to the consensus price target of US$891.62, indicating potential room for upward correction should these growth drivers effectively mate</li>
<li>We&#x27;ve spotted 2 weaknesses for Eli Lilly you should be aware of, and 1 of them is a bit unpleasant.</li>
<li>This article by Simply Wall St is general in nature.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Eli%20Lilly%20%28LLY%29%20Announces%20Promising%20Results%20For%20Jaypirca%20In%20CLL%20Phase%203%20Trial%0A%E2%80%A2%20Pharmaceuticals%20industry%2C%20which%20had%20an%2011.5%25%20decline.%0A%E2%80%A2%20market%2C%20which%20gained%2020.8%25%20over%20the%20past%20year%2C%20and%20the%20U.S.%0A%E2%80%A2%20This%20announcement%20likely%20played%20a%20key%20role%20in%20the%20company%E2%80%99s%2016%25%20share%20price%20rise%20over%20the%20past%20month.%0A%E2%80%A2%20Over%20the%20past%20five%20years%2C%20Eli%20Lilly%27s%20total%20shareholder%20return%2C%20inclusive%20of%20share%20price%20appreciation%20and%20dividends%2C%20reached%20416.18%25%2C%20demonstrating%20significant%20longer-term%20performance.%0A%E2%80%A2%20Currently%2C%20the%20company%27s%20shares%20trade%20at%20US%24727.21%2C%20showing%20a%20considerable%20discount%20to%20the%20consensus%20price%20target%20of%20US%24891.62%2C%20indicating%20potential%20room%20for%20upward%20correction%20should%20these%20growth%20drivers%20effectively%20mate%0A%E2%80%A2%20We%27ve%20spotted%202%20weaknesses%20for%20Eli%20Lilly%20you%20should%20be%20aware%20of%2C%20and%201%20of%20them%20is%20a%20bit%20unpleasant.%0A%E2%80%A2%20This%20article%20by%20Simply%20Wall%20St%20is%20general%20in%20nature.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Feli-lilly-lly-announces-promising-results-for-jaypirca-in-cll-phase-3-trial%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/eli-lilly-lly-announces-promising-172558054.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>